Carlos Arteaga Archives
VICC investigators land support from Komen Foundation
Sep. 28, 2017—Three breast cancer investigators from Vanderbilt-Ingram Cancer Center (VICC) have been awarded research grants from Susan G. Komen, a nonprofit foundation devoted to supporting cancer research, community health outreach, advocacy and public policy initiatives.
Breast Cancer Genomic Profiling Reveals Clues to Treatment Resistance
Aug. 9, 2017—Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers.
Arteaga to direct UT Southwestern cancer center
Jul. 13, 2017—Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies (C2T2), director of the Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of Oncology Programs at the UT Southwestern Medical Center in Dallas.
Precision medicine already changing cancer treatment strategies
May. 26, 2016—The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment.
Public invited to learn about VICC precision cancer medicine
Apr. 27, 2016—Leading cancer investigators from Vanderbilt-Ingram Cancer Center will unveil the latest in cancer research during a community event May 10.
Komen, VICC partnership bolsters breast cancer research
Oct. 8, 2015—For more than twenty years, Vanderbilt-Ingram Cancer Center’s (VICC) primary source of outside funding has been provided by the National Institutes of Health. But in breast cancer, Susan G. Komen, a nonprofit dedicated to breast cancer research and community services, has been a significant sponsor of research and patient care support.
Arteaga lauded for cancer research contributions
Aug. 27, 2015—Carlos L. Arteaga, M.D., the Donna S. Hall Professor of Breast Cancer and director of the Center for Cancer Targeted Therapies and the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been recognized for his cancer research efforts by the American-Italian Cancer Foundation (AICF).
Jansen’s cancer research efforts garner recognition
May. 14, 2015—Valerie Malyvanh Jansen, M.D., Ph.D., a third-year medical oncology fellow, recently received several national awards and grants, as well as a Vanderbilt-Ingram Cancer Center fellowship, in recognition of her translational cancer research.
VUMC’s Arteaga named a fellow of the AACR Academy
Feb. 26, 2015—Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies and director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been named a fellow of the AACR Academy.
Cancer organizations call for regulation of e-cigarettes
Jan. 15, 2015—Two leading cancer organizations are calling for regulation of e-cigarettes and other electronic nicotine delivery systems (ENDS).
Gene mutation linked to breast cancer therapy resistance
Nov. 20, 2014—A group of Vanderbilt-led investigators has identified a new gene mutation that may explain why some breast cancer patients do not respond to anti-hormone therapy.
Improving breast cancer chemo by testing tumors in a dish
Oct. 28, 2014—A team of biomedical engineers has developed a new "tumor-in-a-dish" technology that promises to improve the effectiveness of chemotherapy.
